SENSEX
NIFTY
GOLD
USD/INR

Weather

image 17    C

Opinion News

The Economic Times

Opinion / The Economic Times

details

Semaglutide patent expiry: Indias next big public health inflection point

The expiry of a key patent for semaglutide in India opens doors for affordable weight-loss and diabetes drugs. Indian pharmaceutical companies can now produce generic versions, potentially lowering prices by up to 90%. This expansion promises wider access to crucial metabolic therapies, impacting public health and the economy.

19 Mar 2026 11:53 pm